Nem invazív fibrosisdiagnosztika krónikus C-hepatitisben: aszpartát-aminotranszferáz/thrombocyta hányadosindex (APRI) és tranziens elasztográfia (FibroScan)

Research output: Article

15 Citations (Scopus)

Abstract

Although liver biopsy is the gold standard for the diagnosis of liver disease, non-invasive tests may also play a role in the evaluation of liver fibrosis. Authors studied two fibrosis markers, aspartate-aminotransferase/ platelet ratio index (APRI) and liver stiffness (LS) measurement to assess fibrosis in different forms of chronic hepatitis C virus (HCV) infection. Patients and methods: out of 119 HCV-infected patients 75 had biopsy-proven chronic hepatitis C, 24 had HCV-cirrhosis, 20 individuals were symptom-free HCV-carriers with persistently normal alanine-aminotransferase and 30 healthy blood donors served as controls. Wai's APRI score was calculated from aspartate-aminotransferase and platelet number. For LS measurement transient elastography (FibroScan) was applied. METAVIR fibrosis score was determined by liver biopsy. Results: In patients with chronic hepatitis C infection both fibrosis markers were significantly elevated comparing to normal controls and the markers were the highest in HCV-associated cirrhosis. Values of symptom-free HCV-carriers corresponded to those obtained from healthy controls. Both APRI and LS results correlated with the METAVIR score. LS identified fibrosis better than APRI. Using a novel sequential algorithm that comprises APRI and LS for assessment of fibrosis, 47.8% of HCV patients did not need biopsy for diagnosing significant (F≥2) fibrosis. Conclusion: both fibrosis markers, particularly in combination, may represent a useful option in the noninvasive assessment of fibrosis in HCV infection.

Original languageHungarian
Pages (from-to)1951-1955
Number of pages5
JournalOrvosi Hetilap
Volume151
Issue number47
DOIs
Publication statusPublished - nov. 1 2010

Fingerprint

Elasticity Imaging Techniques
Chronic Hepatitis C
Aspartate Aminotransferases
Fibrosis
Blood Platelets
Hepacivirus
Transaminases
Liver
Biopsy
Virus Diseases
Blood Donors
Alanine Transaminase
Platelet Count
Liver Cirrhosis
Liver Diseases

Keywords

  • aspartate-aminotransferase/platelet ratio index (APRI)
  • fibrosis
  • hepatitis C virus
  • transient elastograph

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{e93f07313fd24f7a8f28d83d461c5add,
title = "Nem invaz{\'i}v fibrosisdiagnosztika kr{\'o}nikus C-hepatitisben: aszpart{\'a}t-aminotranszfer{\'a}z/thrombocyta h{\'a}nyadosindex (APRI) {\'e}s tranziens elasztogr{\'a}fia (FibroScan)",
abstract = "Although liver biopsy is the gold standard for the diagnosis of liver disease, non-invasive tests may also play a role in the evaluation of liver fibrosis. Authors studied two fibrosis markers, aspartate-aminotransferase/ platelet ratio index (APRI) and liver stiffness (LS) measurement to assess fibrosis in different forms of chronic hepatitis C virus (HCV) infection. Patients and methods: out of 119 HCV-infected patients 75 had biopsy-proven chronic hepatitis C, 24 had HCV-cirrhosis, 20 individuals were symptom-free HCV-carriers with persistently normal alanine-aminotransferase and 30 healthy blood donors served as controls. Wai's APRI score was calculated from aspartate-aminotransferase and platelet number. For LS measurement transient elastography (FibroScan) was applied. METAVIR fibrosis score was determined by liver biopsy. Results: In patients with chronic hepatitis C infection both fibrosis markers were significantly elevated comparing to normal controls and the markers were the highest in HCV-associated cirrhosis. Values of symptom-free HCV-carriers corresponded to those obtained from healthy controls. Both APRI and LS results correlated with the METAVIR score. LS identified fibrosis better than APRI. Using a novel sequential algorithm that comprises APRI and LS for assessment of fibrosis, 47.8{\%} of HCV patients did not need biopsy for diagnosing significant (F≥2) fibrosis. Conclusion: both fibrosis markers, particularly in combination, may represent a useful option in the noninvasive assessment of fibrosis in HCV infection.",
keywords = "aspartate-aminotransferase/platelet ratio index (APRI), fibrosis, hepatitis C virus, transient elastograph",
author = "A. P{\'a}r and G. P{\'a}r",
year = "2010",
month = "11",
day = "1",
doi = "10.1556/OH.2010.28978",
language = "Hungarian",
volume = "151",
pages = "1951--1955",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Nem invazív fibrosisdiagnosztika krónikus C-hepatitisben

T2 - aszpartát-aminotranszferáz/thrombocyta hányadosindex (APRI) és tranziens elasztográfia (FibroScan)

AU - Pár, A.

AU - Pár, G.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Although liver biopsy is the gold standard for the diagnosis of liver disease, non-invasive tests may also play a role in the evaluation of liver fibrosis. Authors studied two fibrosis markers, aspartate-aminotransferase/ platelet ratio index (APRI) and liver stiffness (LS) measurement to assess fibrosis in different forms of chronic hepatitis C virus (HCV) infection. Patients and methods: out of 119 HCV-infected patients 75 had biopsy-proven chronic hepatitis C, 24 had HCV-cirrhosis, 20 individuals were symptom-free HCV-carriers with persistently normal alanine-aminotransferase and 30 healthy blood donors served as controls. Wai's APRI score was calculated from aspartate-aminotransferase and platelet number. For LS measurement transient elastography (FibroScan) was applied. METAVIR fibrosis score was determined by liver biopsy. Results: In patients with chronic hepatitis C infection both fibrosis markers were significantly elevated comparing to normal controls and the markers were the highest in HCV-associated cirrhosis. Values of symptom-free HCV-carriers corresponded to those obtained from healthy controls. Both APRI and LS results correlated with the METAVIR score. LS identified fibrosis better than APRI. Using a novel sequential algorithm that comprises APRI and LS for assessment of fibrosis, 47.8% of HCV patients did not need biopsy for diagnosing significant (F≥2) fibrosis. Conclusion: both fibrosis markers, particularly in combination, may represent a useful option in the noninvasive assessment of fibrosis in HCV infection.

AB - Although liver biopsy is the gold standard for the diagnosis of liver disease, non-invasive tests may also play a role in the evaluation of liver fibrosis. Authors studied two fibrosis markers, aspartate-aminotransferase/ platelet ratio index (APRI) and liver stiffness (LS) measurement to assess fibrosis in different forms of chronic hepatitis C virus (HCV) infection. Patients and methods: out of 119 HCV-infected patients 75 had biopsy-proven chronic hepatitis C, 24 had HCV-cirrhosis, 20 individuals were symptom-free HCV-carriers with persistently normal alanine-aminotransferase and 30 healthy blood donors served as controls. Wai's APRI score was calculated from aspartate-aminotransferase and platelet number. For LS measurement transient elastography (FibroScan) was applied. METAVIR fibrosis score was determined by liver biopsy. Results: In patients with chronic hepatitis C infection both fibrosis markers were significantly elevated comparing to normal controls and the markers were the highest in HCV-associated cirrhosis. Values of symptom-free HCV-carriers corresponded to those obtained from healthy controls. Both APRI and LS results correlated with the METAVIR score. LS identified fibrosis better than APRI. Using a novel sequential algorithm that comprises APRI and LS for assessment of fibrosis, 47.8% of HCV patients did not need biopsy for diagnosing significant (F≥2) fibrosis. Conclusion: both fibrosis markers, particularly in combination, may represent a useful option in the noninvasive assessment of fibrosis in HCV infection.

KW - aspartate-aminotransferase/platelet ratio index (APRI)

KW - fibrosis

KW - hepatitis C virus

KW - transient elastograph

UR - http://www.scopus.com/inward/record.url?scp=78649298535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649298535&partnerID=8YFLogxK

U2 - 10.1556/OH.2010.28978

DO - 10.1556/OH.2010.28978

M3 - Article

C2 - 21071307

AN - SCOPUS:78649298535

VL - 151

SP - 1951

EP - 1955

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -